Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Allergic Reactions02:06

Allergic Reactions

Overview
Allergic Reactions: Anaphylaxis01:30

Allergic Reactions: Anaphylaxis

Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin, heparin),...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Asthma I: Introduction01:28

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
Allergic Drug Reactions01:27

Allergic Drug Reactions

Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing numerous...
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Microarrayed Allergen Molecules Distinguish IgE Sensitisation to Blomia tropicalis and Dermatophagoides pteronyssinus.

Allergy·2026
Same author

Profound Impact of Local Climatic Conditions on IgE Sensitization Profiles: Evidence from Argentine Cities.

International journal of molecular sciences·2025
Same author

Molecular IgE Reactivity Profiling With Micro-Arrayed Allergens Reveals Distinct Interregional Patterns of Sensitization and a Hypoallergenic Region in TĂĽrkiye.

Allergy·2025
Same author

Occupational Mite Allergy and Asthma: An EAACI Task Force Report.

Allergy·2025
Same author

Immunoproteomics reveal increased serum IgG3/5 binding to <i>Dermatophagoides</i> and yeast protein antigens in severe equine asthma in a preliminary study.

Frontiers in immunology·2024
Same author

Predicting Blomia tropicalis allergens using a multiomics approach.

Clinical and translational allergy·2023
Same journal

An accessible, absorbance-based plate reader assay to assess cumulative exposure of blood plasma & serum to thawed conditions.

Methods (San Diego, Calif.)·2026
Same journal

EC-isHCR: A rapid method for in situ hybridization chain reaction in diverse animal samples.

Methods (San Diego, Calif.)·2026
Same journal

Single-Molecule methods to investigate mechanisms of transcription by RNA polymerase of Mycobacterium tuberculosis.

Methods (San Diego, Calif.)·2026
Same journal

Detection and sequencing of Usutu virus during mosquito surveillance: Use of multiple assays and techniques for identification at low levels.

Methods (San Diego, Calif.)·2026
Same journal

Experimental validation of an AI-driven digital healthcare platform for oral health behavior and plaque assessment among vietnamese children.

Methods (San Diego, Calif.)·2026
Same journal

Zeta potential: An efficient and cost-effective alternative for investigating cell-surface interactions.

Methods (San Diego, Calif.)·2026
See all related articles

Related Experiment Video

Updated: May 9, 2026

Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation
08:44

Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation

Published on: May 30, 2020

Recombinant house dust mite allergens.

Susanne Vrtala1, Hans Huber2, Wayne R Thomas3

  • 1Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.

Methods (San Diego, Calif.)
|August 6, 2013
PubMed
Summary
This summary is machine-generated.

Developing new house dust mite (HDM) allergy vaccines uses recombinant allergens. These modified allergens offer safer and more effective immunotherapy for allergic patients by reducing side effects while maintaining immune response.

Keywords:
House dust mite allergyImmunotherapyRecombinant allergens

More Related Videos

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber
08:47

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber

Published on: March 3, 2023

Related Experiment Videos

Last Updated: May 9, 2026

Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation
08:44

Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation

Published on: May 30, 2020

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber
08:47

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber

Published on: March 3, 2023

Area of Science:

  • Allergy and Immunology
  • Molecular Biology
  • Vaccine Development

Background:

  • House dust mites (HDM) are a major global allergen source, causing sensitization in over 50% of allergic individuals.
  • Current specific immunotherapy with HDM extracts faces challenges in standardization and can cause severe side effects.
  • Molecular biology has identified over 20 HDM allergen groups, enabling new therapeutic approaches.

Purpose of the Study:

  • To outline the development of novel vaccines for house dust mite allergy using recombinant allergens.
  • To create safer and more effective immunotherapy options for HDM allergy patients.
  • To leverage advancements in molecular biology for improved allergy treatment.

Main Methods:

  • Selection of prevalent HDM species and identification of key allergens for vaccine inclusion.
  • Modification of selected HDM allergens into hypoallergenic variants with reduced allergenic activity.
  • Evaluation of modified allergen derivatives for retained immunogenicity and reduced allergenicity.

Main Results:

  • Recombinant HDM allergens can be produced with consistent quality and defined concentrations.
  • Hypoallergenic allergen derivatives demonstrate reduced allergenic activity while maintaining immunogenicity.
  • Successful immunotherapy trials with recombinant pollen allergens suggest potential for HDM vaccines.

Conclusions:

  • Recombinant HDM vaccines hold promise for improving the safety and efficacy of immunotherapy for HDM allergy.
  • Hypoallergenic allergen derivatives are strong candidates for developing next-generation HDM allergy vaccines.
  • This approach aims to provide a standardized, well-tolerated, and effective treatment for millions affected by HDM allergy.